Sign inJoin waitlistJoin the waitlist

Paul Gilman

Hematology & Oncology

Credentials: · ·

History

SIDNEY KIMMEL MEDICAL COLLEGE AT THOMAS JEFFERSON UNIVERSITY
1979–1982
New England Deaconess Hospital
1976–1979
Sidney Kimmel Medical College at Thomas Jefferson University
1972–1976

Research

Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial
JAMA · 2013 · 778 citations
Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
Journal of Clinical Oncology · 2001 · 334 citations
The symptom burden of cancer: Evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice…
Cancer · 2013 · 271 citations

Zonera Ali
5 papers · 1 as a fellow
Diana Martinez
3 papers
JH
Julie Hibbs
3 papers · 2 as a fellow
Katherine Ruiz
3 papers · 1 as a resident
MW
Marisa Weiss
3 papers
Michael Fisch
3 papers
Al Benson
2 papers
Arezoo Ghaneie
2 papers
Deric Savior
2 papers · 1 as a fellow
EL
Elaine Le
2 papers
Erik Zeger
2 papers
MW
Matthias Weiss
2 papers

Grants

Main Line Health CCOP
National Cancer Institute · U10
Contact PI · $5.5M · Lankenau Institute for Medical Research
1994–2012

Clinical trials

Zip-Stitch® in Minimally-Invasive Surgery (ZIMS) - Safety & Efficacy in Hysterectomy
Principal investigator · Completed
ZSX Medical LLC
2023–2025
An External Control Arm Study in Non-Small Cell Lung Cancer
Site PI · Recruiting
N-Power Medicine
2026–2029
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Site PI · Recruiting · Phase 3
Stemline Therapeutics, Inc.
2024–2032
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2023–2030